1. Andersen RM, Davidson PL. Improving access to care in America. In: Anderson RM, Rice TH, Kominski GF (eds). Changing the U. S. Health Care System. 2nd ed. San Francisco: Jossey-Bass 2001.
2. Andersen RM. Revisiting the behavioral model and access to medical care: does it matter? J Health Soc Behav. Mar 1995; 36(1): 1–10.
3. Aday LA, Andersen RM. Equity of access to medical care: a conceptual and empirical overview. Med Care. Dec 1981; 19 (Suppl 12): 4–27.
4. Griffiths V, Ahmed-Jushuf I, Cassell JA. Understanding access to genitourinary medicine services. Int J STD AIDS 2004; 15(9): 587–589.
5. Fitzpatrick P, Corcoran N, Fitzpatrick JM. Prostate cancer: how aware is the public? Br J Urol 1998; 82(1): 43–48.
6. Kelley E, Moy E, Stryer D et al. The national healthcare quality and disparities reports: an overview. Med Care 2005; 43 (Suppl 3): I3–I8.
7. Kelley E, Moy E, Dayton E. Health care quality and disparities: lessons from the first national reports. Med Care. Mar 2005; 43 (Suppl 3): I1–I2.
8. Rajfer J, Aronson WJ, Bush PA et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326(2): 90–94.
9. Lee TH. My insurance company won't pay for my prescription for Viagra without a letter from my doctor saying that I have been evaluated. As far as I know, I am the only one who can tell whether I have impotence. What does the insurance company want? Harv Heart Lett 1999; 9(7): 7.
10. Walsh DC, Connor E, Tracey LV et al. Posthospital convalescence and return to work. Health Aff (Millwood) 1989; 8(3): 76–90.
11. Luz J, Green MS. Sickness absenteeism from work-a critical review of the literature. Public Health Rev 1997; 25(2): 89–122.
12. Stewart WF, Ricci JA, Chee E et al. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003; 45(12): 1234–1246.
13. Muńoz E, Mallett E, Gerold T et al. Access and quality of care for urology patients under diagnostic related group reimbursement. J Urol 1988; 139(6): 1256–1259.
14. Kahn KL, Rubenstein LV, Draper D et al. The effects of the DRG-based prospective payment system on quality of care for hospitalized Medicare patients. An introduction to the series. JAMA 1990; 264(15): 1953–1955.
15. Muńoz E, Goldstein J, Lory MH et al. The DRG hospital payment system, surgical readmissions and cost containment. Am Surg 1990; 56(11): 683–687.
16. Muńoz E, Boiardo R, Mulloy K et al. Economies of scale, physician volume for urology patients, and DRG prospective hospital payment system. Urology 1990; 36(5): 471–476.
17. Muńoz E, Mulloy K, Goldstein J et al. Physician's patient load per DRG, the consumption of hospital resources, and the incentives of the DRG prospective payment system. Acad Med 1990; 65(8): 533–538.
18. Muńoz E, Barrau L, Goldstein J et al. DRG prospective, "all payor systems," financial risk, and hospital cost in pulmonary medicine non CC stratified DRGs. Chest 1988; 94(4): 855–861.
19. Shepard DS, Thompson MS. First principles of cost-effectiveness analysis in health. Public Health Rep 1979; 94(6): 535–543.
20. Chandhoke PS, DeAntoni E. Cost-effectiveness analysis: application to endourology. J Endourol 1998; 12(6): 485–491.
21. Henriksson P, Edhag O. Cost-effectiveness comparison of estrogen therapy and orchidectomy in patients with prostatic cancer. Int J Technol Assess Health Care 1987; 3(4): 523–529.
22. Manca A, Sculpher MJ, Ward K et al. A cost-utility analysis of tension-free vaginal tape versus colposuspension for primary urodynamic stress incontinence. BJOG 2003; 110(3): 255–262.
23. Smith TJ, Hillner BE, Desch CE. Efficacy and costeffectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst 1993; 85(18): 1460–1474.
24. Saigal CS, Gornbein J, Nease R et al. Predictors of utilities for health states in early stage prostate cancer. J Urol 2001; 166(3): 942–946.
25. Saigal CS, Gornbein J, Reid K et al. Stability of time trade-off utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002; 11(5): 405–414.
26. Nease RF Jr, Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. Med Decis Making 1994; 14(4): 382–392.
27. Albertsen PC, Nease RF Jr, Potosky AL. Assessment of patient preferences among men with prostate cancer. J Urol 1998; 159(1): 158–163.
28. Bennett CL, Greenfield S, Aronow H et al. Patterns of care related to age of men with prostate cancer. Cancer 1991; 67(10): 2633–2641.
29. Joudi FN, Smith BJ, O'Donnell MA et al. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology 2003; 62(6): 1083–1088.
30. Bird VG, Fallon B, Winfield HN. Practice patterns in the treatment of large renal stones. J Endourol 2003; 17(6): 355–363.
31. O'Leary MP, Gee WF, Holtgrewe HL et al. 1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol 2000; 164(4): 1311–1316.
32. Fallon E, Ercole B, Lee C et al. Contemporary management of ureteropelvic junction obstruction: practice patterns in Minnesota. J Endourol 2005; 19(1): 41–44.
33. Wennberg JE. Practice variations and health care reform: connecting the dots. Health Aff (Millwood) 2004; Suppl Web Exclusive: VAR140–VAR144.
34. Weinstein JN, Bronner KK, Morgan TS et al. Trends and geographic variations in major surgery for degenerative diseases of the hip, knee, and spine. Health Aff (Millwood) 2004; Suppl Web Exclusive: VAR81–VAR89.
35. Fisher ES, Wennberg DE, Stukel TA et al. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med 2003; 138(4): 273–287.
36. Fisher ES, Wennberg DE, Stukel TA et al. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med 2003; 138(4): 288–298.
37. Kramolowsky EV, Wood NL, Rollins KL et al. The role of the physician in effecting change in hospital charge for radical prostatectomy. J Am Coll Surg 1995; 180(5): 513–518.
38. Kramolowsky EV, Wood NL, Rollins KL et al. Impact of physician awareness on hospital charges for radical retropubic prostatectomy. J Urol 1995; 154(1): 139–142.
39. Sage WM, Kessler R, Sommers LS et al. Physiciangenerated cost containment in transurethral prostatectomy. J Urol 1988; 140(2): 311–315.
40. Cuckow PM. Cost of urology: financial audit in a clinical department. BMJ 1992; 305(6856): 743–746.
41. Cuckow PM. Costs can and must be a component of surgical audit. Ann R Coll Surg Engl 1992; 74(6): 406–410. Discussion 410–401.
42. Forrest JB, Ritchie WP Jr, Hudson M et al. Cost containment through cost awareness: a strategy that failed. Surgery 1981; 90(2): 154–158.
43. Carter GM, Melnick GA. How services and costs vary by day of stay for Medicare hospital stays. Santa Monica, CA: The RAND Corporation 1990.
44. Benoit RM, Grönberg H, Naslund MJ. A quantitative analysis of the costs and benefits of prostate cancer screening. Prostate Cancer Prostatic Dis 2001; 4(3): 138–145.
45. Perlman ES, Rosenfield AT, Wexler JS et al. CT urography in the evaluation of urinary tract disease. J Comput Assist Tomogr 1996; 20(4): 620–626.
46. Grossfeld GD, Carroll PR. Evaluation of asymptomatic microscopic hematuria. Urol Clin North Am 1998; 25(4): 661–676.
47. Mor Y, Leibovitch I, Golomb J et al. Routine cystoscopy before radical prostatectomy: is it justified? Urology 2001; 57(5): 946–948.
48. Shaw GT. The golden hour: how to spend your time and money in trauma radiology. Radiology 2004; 232(2): 622–623. Author reply 623–624.
49. Haffer SC, Bowen SE. Measuring and improving health outcomes in Medicare: the Medicare HOS program. Health Care Financ Rev 2004; 25(4): 1–3.
50. Holtgrewe HL. Managed care and its impact on American urology. Urology 1998; 51 (Suppl 5A): 31–35.
51. Holtgrewe HL. The economics of urologic practice in the twenty-first century. Urol Clin North Am 1998; 25(1): 1–13.
52. Greenwald HP. HMO membership, copayment, and initiation of care for cancer: a study of working adults. Am J Public Health 1987; 77(4): 461–466.
53. Greenwald HP, Henke CJ. HMO membership, treatment, and mortality risk among prostatic cancer patients. Am J Public Health 1992; 82(8): 1099–1104.
54. Litwin MS, Saigal CS, Yano EM et al. Urologic diseases in America Project: analytical methods and principal findings. J Urol 2005; 173(3): 933–937.
55. Williams RD. Urologic Diseases in America project. J Urol 2005; 173(3): 679.
56. Iezzoni LI, Ash AS, Shwartz M et al. Judging hospitals by severity-adjusted mortality rates: the influence of the severity-adjustment method. Am J Public Health 1996; 86(10): 1379–1387.
57. Iezzoni LI. An introduction to risk adjustment. Am J Med Qual 1996; 11(1): S8–S11.58. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40(5): 373–383.
59. Greenfield S, Apolone G, McNeil BJ et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993; 31(2): 141–154.
60. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus. J Chronic Dis 1974; 27(7–8): 387–404.
61. Greenfield S, Sullivan L, Dukes KA et al. Development and testing of a new measure of case mix for use in office practice. Med Care 1995; 33 (Suppl 4): AS47–AS55.
62. Crabtree HL, Gray CS, Hildreth AJ et al. The Comorbidity Symptom Scale: a combined disease inventory and assessment of symptom severity. J Am Geriatr Soc. 2000 Dec; 48(12): 1674–1678.
63. Di Gangi Herms AM, Pinggera GM, De Jonge P et al. Assessing health care needs and clinical outcome with urological case complexity: a study using INTERMED. Psychosomatics. May–Jun 2003; 44(3): 196–203.
64. Litwin MS, Greenfield S, Elkin EP et al. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. May 1 2007; 109(9): 1777–1783.
65. Albertsen PC, Fryback DG, Storer BE et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol Jul 1996; 156(1): 127–132.
66. Bodenheimer T. High and rising health care costs. Part 1: seeking an explanation. Ann Intern Med. May 17 2005; 142(10): 847–854.
67. Corrigan K, Ryan RH. New reimbursement models reward clinical excellence. Healthc Financ Manage. Nov 2004; 58(11): 88–92.
68. Spencer BA, Steinberg M, Malin J et al. Quality-ofcare indicators for early-stage prostate cancer. J Clin Oncol. 2003; 21(10): 1928–1936.
69. Litwin MS, Steinberg M, Malin JL et al. Prostate cancer patient outcomes and choice of providers: development of an infrastructure for quality assessment. Santa Monica, CA: RAND Corporation; 2000.
70. Lohr KN, ed. Medicare: A Strategy for Quality Assurance. Washington, DC: National Academy Press; 1990.
71. Lohr KN, Donaldson MS, Harris-Wehling J. Medicare: a strategy for quality assurance, V: Quality of care in a changing health care environment. QRB Qual Rev Bull 1992; 18(4): 120–126.
72. Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q. Jul 1966; 44(3): Suppl: 166–206.
73. Brook RH, McGlynn EA, Shekelle PG. Defining and measuring quality of care: a perspective from US researchers. Int J Qual Health Care. 2000 Aug; 12(4): 281–295.
74. Brook RH, McGlynn EA, Cleary PD. Quality of health care. Part 2: measuring quality of care. N Engl J Med 1996; 335(13): 966–970.
75. Brook RH, Kamberg CJ, Lohr KN et al. Quality of ambulatory care. Epidemiology and comparison by insurance status and income. Med Care. May 1990; 28(5): 392–433.
76. Nuttall M, van der Meulen J, Phillips N et al. A Systematic Review and Critique of the Literature Relating Hospital or Surgeon Volume to Health Outcomes for 3 Urological Cancer Procedures. J Urol. Dec 2004; 172(6, Part 1 of 2): 2145–2152.
77. Vitale MA, Arons RR, Hyman JE et al. The contribution of hospital volume, payer status, and other factors on the surgical outcomes of scoliosis patients: a review of 3,606 cases in the State of California. J Pediatr Orthop. May–Jun 2005; 25(3): 393–399. 78. Dibra A, Kastrati A, Schuhlen H et al. The relationship between hospital or operator volume and outcomes of coronary patients undergoing percutaneous coronary interventions. Z Kardiol. Apr 2005; 94(4): 231–238.
79. Killeen SD, O'Sullivan MJ, Coffey JC et al. Provider volume and outcomes for oncological procedures. Br J Surg. Apr 2005; 92(4): 389–402.
80. Lyman S, Jones EC, Bach PB et al. The association between hospital volume and total shoulder arthroplasty outcomes. Clin Orthop Relat Res. 2005 Mar (432): 132–137.
81. Lee KT, Chang WT, Huang MC et al. Influence of surgeon volume on clinical and economic outcomes of laparoscopic cholecystectomy. Dig Surg 2004; 21(5–6): 406–412.
82. Katz JN, Barrett J, Mahomed NN et al. Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am 2004; 86-A(9): 1909–1916.
83. Joshi AV, Miller LA. Hospital procedure volume and outcomes. Ann Intern Med. Jun 15 2004; 140(12): 1061–1062; author reply 1062.
84. Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346(15): 1138–1144.
85. Hu JC, Gold KF, Pashos CL et al. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003; 21(3): 401–405.
86. Ellison LM, Heaney JA, Birkmeyer JD. The effect of hospital volume on mortality and resource use after radical prostatectomy. J Urol 2000; 163(3): 867–869.
87. Lu-Yao GL, Potosky AL, Albertsen PC et al. Followup prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 1996; 88(3–4): 166–173.
88. Patel A, Dorey F, Franklin J et al. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 1997; 158(4): 1441–1445.
89. D'Amico AV, Moul J, Carroll PR et al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 2005; 173(5): 1572–1576.
90. Schatzkin A, Freedman LS, Dorgan J et al. Surrogate end points in cancer research: a critique. Cancer Epidemiol Biomarkers Prev 1996; 5(12): 947–953.
91. Guyatt GH, Naylor CD, Juniper E et al. Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. Jama 1997; 277(15): 1232–1237.
92. Guyatt GH, Bombardier C, Tugwell PX. Measuring disease-specific quality of life in clinical trials. CMAJ 1986; 134(8): 889–895.
93. Cella DF, Bonomi AE. Measuring quality of life: 1995 update. Oncology 1995; 9(11 Suppl): 47–60.
94. Strasser S, Aharony L, Greenberger D. The patient satisfaction process: moving toward a comprehensive model. Med Care Rev 1993; 50(2): 219–248.
95. Cleary PD, McNeil BJ. Patient satisfaction as an indicator of quality care. Inquiry 1988; 25(1): 25–36.
96. Hayward RA, McMahon LF jr., Bernard AM. Evaluating the care of general medicine inpatients: how good is implicit review? Ann Intern Med 1993; 118(7): 550–556.
97. Aharony L, Strasser S. Patient satisfaction: what we know about and what we still need to explore. Med Care Rev 1993; 50(1): 49–79.
98. Williams G, Pazdur R, Temple R. Assessing tumorrelated signs and symptoms to support cancer drug approval. J Biopharm Stat 2004; 14(1): 5–21.
99. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM, eds. Quality of Life Assessment:Key issues in the 1990's: Dordrecht:Kluwer Academic Publishers; 1993: 11–64.
100. WHO. Constitution of the World Health Organization, basic documents. Geneva: WHO; 1948.
101. Fossa SD. Quality of life after palliative radiotherapy in patients with hormone- resistant prostate cancer: single institution experience. Br J Urol 1994; 74(3): 345–351.
102. Litwin MS. Measuring health related quality of life in men with prostate cancer. J Urol. 1994; 152(5 Pt 2): 1882–1887.
103. Tulsky DS. An introduction to test theory. Oncology 1990; 4(5): 43–48.
104. Testa MA, Simonson DC. Assesment of quality-oflife outcomes. N Engl J Med 1996; 334(13): 835–840.
105. McSweeny AJ, Creer TL. Health-related quality-oflife assessment in medical care. Dis Mon 1995; 41(1): 1–71.
106. Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer 1991; 67(3 Suppl): 844–850.
107. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991; 12(4 Suppl): 142S–158S.
108. Adler NE, Epel ES, Castellazzo G et al. Relationship of subjective and objective social status with psychological and physiological functioning: preliminary data in healthy white women. Health Psychol 2000; 19(6): 586–592.
109. Nelson EC, Landgraf JM, Hays RD et al. The functional status of patients. How can it be measured in physicians' offices? Med Care 1990; 28(12): 1111–1126.
110. Finlay WM, Lyons E. Methodological issues in interviewing and using self-report questionnaires with people with mental retardation. Psychol Assess 2001; 13(3): 319–335.
111. Fossa SD, Aaronson NK, Newling D et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur.J.Cancer. 1990; 26(11–12): 1133–1136.
112. Litwin MS, Lubeck DP, Henning JM et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998; 159(6): 1988–1992.
113. Slevin ML, Plant H, Lynch D et al. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988; 57(1): 109–112.
114. Fossa SD, Moynihan C, Serbouti S. Patients' and doctors' perception of long-term morbidity in patients with testicular cancer clinical stage I. A descriptive pilot study [see comments]. SupportCare Cancer 1996; 4(2): 118–128.
115. Lampic C, von Essen L, Peterson VW et al. Anxiety and depression in hospitalized patients with cancer: agreement in patient-staff dyads. Cancer Nurs 1996; 19(6): 419–428.
116. Sneeuw KC, Aaronson NK, Sprangers MA et al. Value of caregiver ratings in evaluating the quality of life of patients with cancer. J Clin Oncol 1997; 15(3): 1206–1217.
117. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the
quality of life of patients with chronic disease: a review. J Clin Epidemiol 1992; 45(7): 743–760.
118. Kornblith AB, Herr HW, Ofman US et al. Quality of life of patients with prostate cancer and their spouses: The value of a data base in clinical care. Cancer 1994; 73(11): 2791–2802.
119. Testa MA. Parallel perspectives on quality of life during antihypertensive therapy: impact of responder,survey environment, and questionnaire structure. J Cardiovasc Pharmacol 1993; 21(Suppl 2): S18–25.
120. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989; 27(3 Suppl): S217–232.
121. Fossa SD, Woehre H, Kurth KH et al. Influence of urological morbidity on quality of life in patients with prostate cancer. Eur Urol 1997; 31(Suppl 3): 3–8.
122. McDowell I, Ewell C. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press; 1987.
123. Ware JE, Kosinski M, Keller SK. SF-36 physical and mental health summary scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
124. Ware JE jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–483.
125. Gandek B, Ware JE jr., Aaronson NK et al. Tests of data quality, scaling assumptions, and reliability of the SF- 36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998; 51(11): 1149–1158.
126. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res 1976; 11(4): 478–507.
127. Kaplan RM, Ganiats TG, Sieber WJ et al. The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care 1998; 10(6): 509–520.
128. Kaplan RM, Sieber WJ, Ganiats TG. The quality of well-being scale: comparison of the intervieweradministered version with a self-administered questionnaire. Psychology and Health 1997; 12: 783–791.
129. Kaplan RM, Bush JW. Health-related quality of life measurement for evaluation research and policy analysis. Health Psychology 1982; 1:61–80.
130. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 23(2): 203–235.
131. Anderson JP, Kaplan RM, Berry CC et al. Interday reliability of function assessment for a health status measure. The Quality of Well-Being scale. Med Care 1989; 27(11): 1076–1083.
132. Bergner M, Bobbitt RA, Carter WB et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19(8): 787–805.
133. Bergner M, Bobbitt RA, Pollard WE et al. The sickness impact profile: validation of a health status measure. Med Care 1976; 14(1): 57–67.
134. Hunt SM, McEwen J, McKenna SP. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985; 35(273): 185–188.
135. McDowell IW, Martini CJ, Waugh W. A method for self-assessment of disability before and after hip replacement operations. Br Med J 1978; 2(6141): 857–859.
136. Martini CJ, McDowell I. Health status: patient and physician judgments. Health Serv Res 1976; 11(4): 508–515.
137. Ware J jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3): 220–233.
138. Ware JE, Kosinski M, Keller SD. SF-12: How to score the SF-12 physical and mental health summary scales. 1 ed. Boston, MA: The Health Institute, New England Medical Center; 1995.
139. Gandek B, Ware JE, Aaronson NK et al. Crossvalidation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Asses sment. J Clin Epidemiol 1998; 51(11): 1171–1178.
140. Tannock IF. Management of breast and prostate cancer: how does quality of life enter the equation? Oncology 1990; 4(5): 149–156.